H
2.31
-0.05 (-2.12%)
Penutupan Terdahulu | 2.36 |
Buka | 2.40 |
Jumlah Dagangan | 2,648,367 |
Purata Dagangan (3B) | 4,989,145 |
Modal Pasaran | 358,324,896 |
Harga / Jualan (P/S) | 555.64 |
Harga / Buku (P/B) | 9.94 |
Julat 52 Minggu | |
Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
Margin Operasi (TTM) | -4,484.33% |
EPS Cair (TTM) | -0.690 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 228.93% |
Nisbah Semasa (MRQ) | 3.68 |
Aliran Tunai Operasi (OCF TTM) | -99.38 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.40 M |
Pulangan Atas Aset (ROA TTM) | -42.82% |
Pulangan Atas Ekuiti (ROE TTM) | -249.75% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Humacyte, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.8
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 1.0 |
Osilator Teknikal | -2.5 |
Purata | 0.75 |
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 20.16% |
% Dimiliki oleh Institusi | 39.87% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Maven Securities Ltd | 31 Mar 2025 | 1,049,828 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 25.00 (D. Boral Capital, 982.25%) | Beli |
Median | 14.00 (506.06%) | |
Rendah | 4.00 (HC Wainwright & Co., 73.16%) | Beli |
Purata | 14.33 (520.35%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 2.10 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
D. Boral Capital | 09 Jun 2025 | 25.00 (982.25%) | Beli | 2.56 |
13 May 2025 | 25.00 (982.25%) | Beli | 1.73 | |
Benchmark | 14 May 2025 | 14.00 (506.06%) | Beli | 1.87 |
HC Wainwright & Co. | 14 May 2025 | 4.00 (73.16%) | Beli | 1.87 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
09 Jun 2025 | Pengumuman | Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting |
02 Jun 2025 | Pengumuman | Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 |
19 May 2025 | Pengumuman | Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq |
13 May 2025 | Pengumuman | Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update |
09 May 2025 | Pengumuman | Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |